Evidence map›Paper›PMID 30030392›Full record

ArticleThe British journal of ophthalmology2019

Identification of a novel pathogenic missense mutation in

Laura Bryant, Olga Lozynska, Anson Marsh, Tyler E Papp, Lucas van Gorder, Leona W Serrano, Xiaowu Gai, Albert M Maguire, Tomas S Aleman, Jean Bennett

Open access · hybridAbstract read
In one paragraph

Article in The British journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. A CombinedFrontiers in genetics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Laura BryantCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Olga LozynskaCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Anson MarshCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Tyler E PappCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Lucas van GorderCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Leona W SerranoDepartment of Ophthalmology and CAROT, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, USA.
Xiaowu GaiCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Albert M MaguireDepartment of Ophthalmology and CAROT, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, USA.
Tomas S AlemanDepartment of Ophthalmology and CAROT, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, USA jebennet@pennmedicine.upenn.edu aleman@pennmedicine.upenn.edu.
Jean BennettCenter for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA jebennet@pennmedicine.upenn.edu aleman@pennmedicine.upenn.edu.ORCID 0000-0003-3378-8263
Penn Presbyterian Medical Center · USUniversity of Southern California · US

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Qi N Cui · 1985 to 2026
$19.5M
RESEARCH ON NORMAL AND ABNORMAL MECHANISMS OF VISIONST32EY007035 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Diego Contreras, Jessica I.W. Morgan · 1985 to 2026
$4.9M
NEI NIH HHS P30 EY001583NEI NIH HHS T32 EY007035
6 · The paper itself

Abstract

backgroundVariants in

methodsWe performed whole exome sequencing to identify possible pathogenic mutations in the proband of a family with adRP. Available affected family members had a full ophthalmological evaluation including kinetic and two-colour dark adapted static perimetry, electroretinography and multimodal imaging of the retina. Two patients had evaluations covering nearly 20 years. We carried out segregation analysis of the probable mutation,

results

conclusionsc.590T>C is a novel pathogenic variant in

Indexed as

Mutation, MissenseVisual AcuityAdultDNADNA Mutational AnalysisElectroretinographyExome SequencingEye ProteinsHumansMalePedigreeRetinaRetinitis PigmentosaRNA SplicingTomography, Optical CoherenceDNAEye ProteinsPRPF31 protein, humangenetic diagnosisPRPF31generetinitis pigmentosa

Identifiers

PMID30030392
PMCPMC6582727
OpenAlexW2883220340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.